Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV infection on second line treatment in the 2lady trial for at least 48 weeks~* VL ≤ 200 copies/ml since at least 6 months~* No change in ART in the last 3 months previous to the study~* CD4\> 100 cells/ml~* Signed informed consent~* Adherence \>90~Exclusion Criteria:~* Previous viral failure (at least 2 consecutive HIV RNA \>1000 copies/ml) while receiving a PI~* Ongoing pregnancy and breast feeding women~* HBsAg positive patients~* opportunistic infection or any severe or progressive disease ongoing or treated in the 3 months before screening~* Subject who in the investigator's opinion is unable to complete the study~* History or symptoms of HIV encephalopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- monoPI - boosted lopinavir or boosted darunavir (Type: ACTIVE_COMPARATOR): boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)~This arm has been stopped on advise of DSMB (approved by Scientific Committee), patients are switched to standard second line triple therapy and followed until the end of the study at week 96.
- bi therapy - (boosted lopinavir or darunavir) + lamivudine (Type: ACTIVE_COMPARATOR): boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) with lamivudine 300 mg QD or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)with lamivudine 300 mg QD

Based on this trial design, predict the completion outcome and termination type (if applicable).